New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent

A Phase 3 trial of a personalized mRNA vaccine for melanoma has shown a 40% reduction in the risk of melanoma recurrence. The vaccine is tailored to a patient's specific tumor, demonstrating the potential of mRNA vaccines in cancer treatment.